Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Tissue and Blood Biomarkers From Patients With Stage III or Stage IV Melanoma Treated With Ipilimumab With or Without Sargramostim

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2011 by National Cancer Institute (NCI).
Recruitment status was  Not yet recruiting
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: December 8, 2011
Last updated: NA
Last verified: December 2011
History: No changes posted

RATIONALE: Studying samples of tissue and blood in the laboratory from patients treated with ipilimumab with or without sargramostim may help doctors learn more about the effects of ipilimumab and sargramostim on cells. It may also help doctors understand how well patients respond to treatment.

PURPOSE: This research trial studies tissue and blood biomarkers in patients with stage III melanoma or stage IV melanoma treated with ipilimumab with or without sargramostim.

Condition Intervention
Melanoma (Skin)
Genetic: RNA analysis
Genetic: in situ hybridization
Genetic: polymerase chain reaction
Other: enzyme-linked immunosorbent assay
Other: flow cytometry
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis

Study Type: Observational
Official Title: Correlative Analyses of Specimens From Eastern Cooperative Group Study E1608

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Primary brisk lymphocytic infiltrates associated with better outcomes (overall survival, progression-free survival, and clinical response) [ Designated as safety issue: No ]
  • Mechanisms involved in effective anti-tumor immune response [ Designated as safety issue: No ]
  • Biomarkers predictive of immune reaction with regard to treatment response [ Designated as safety issue: No ]
  • Changes in circulating immune effector cells (T-cell, B-cell, NK, and NK T cells), circulating plasmacytoid dendritic cell (DC), myeloid DC, and melanoma-associated antigen-specific T cell associated with treatment response [ Designated as safety issue: No ]
  • Effects of the addition of systemic GM-CSF to ipilimumab on regulatory immune function [ Designated as safety issue: No ]
  • Anti-cancer immunological activity and effects of the addition of systemic GM-CSF to ipilimumab therapy [ Designated as safety issue: No ]

Estimated Enrollment: 270
Study Start Date: September 2012
Estimated Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Detailed Description:


  • To compare the pathology of primary melanomas, melanoma metastases, and post-treatment melanoma metastases in relation to clinical outcomes for patients receiving ipilimumab plus sargramostim (GM-CSF) and patients receiving ipilimumab alone.
  • To determine the effects of the addition of systemic GM-CSF to ipilimumab on effector immune function in patients with metastatic melanoma.
  • To determine the effects of the addition of systemic GM-CSF to ipilimumab on regulatory immune function in patients with metastatic melanoma.
  • To determine the effects of the addition of systemic GM-CSF to ipilimumab on anti-tumor humoral immunity in patients with metastatic melanoma.

OUTLINE: Serum, peripheral blood mononuclear cells, and tumor tissue (from primary tumor and post-treatment biopsies) samples are analyzed for biomarkers predictive of clinical outcomes, immune function, and anti-tumor humoral immunity by IHC, RT-PCR, flow cytometry, ELISPOT assays, and ELISA.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Diagnosis of measurable unresectable stage III or stage IV melanoma
  • Treated with ipilimumab with or without sargramostim on clinical trial ECOG-E1608
  • Primary tumor tissue and optional post-treatment biopsies of tumors from easily accessible tissues


  • ECOG performance status 0 or 1


  • See Disease Characteristics
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01489423

Sponsors and Collaborators
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)
Principal Investigator: F. Stephen Hodi, MD Dana-Farber Cancer Institute
  More Information

Additional Information:
Responsible Party: Robert L. Comis, ECOG Group Chair's Office Identifier: NCT01489423     History of Changes
Other Study ID Numbers: CDR0000718014  ECOG-E1608T1 
Study First Received: December 8, 2011
Last Updated: December 8, 2011
Health Authority: Unspecified

Keywords provided by National Cancer Institute (NCI):
stage IIIC melanoma
stage IV melanoma
recurrent melanoma

Additional relevant MeSH terms:
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas processed this record on October 21, 2016